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1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for postpartum endometritis and
infection following incomplete or complete abortion as adverse events
following maternal immunization
Remarkable progress has been made in the implementation of
vaccinations against infectious diseases worldwide. Immunization
of pregnant women is important because pregnancy is thought to
modulate the immune system to tolerate a growing fetus, and this,
along with the physiologic changes of pregnancy, may increase
susceptibility to certain infectious diseases [1]. Immunizing the
mother also provides direct protection via transplacental transfer
of antibodies for the fetus during pregnancy and for the neonate
following delivery. Pregnancy outcomes related to the administra-
tion of immunizations during pregnancy, however, have been less
well studied. In particular, puerperal sepsis (infection of the femalegenital tract following childbirth or abortion/miscarriage) has not
been well studied following maternal immunization. Puerperal
sepsis is responsible for over 10% of maternal deaths worldwide
and disproportionately occur in low- and middle-income countries
(LMICs) [2,3]. Puerperal sepsis is defined by the World Health
Organization (WHO) as infection of the genital tract occurring
any time between the rupture of membranes or labor and the
42nd day postpartum. This definition encompasses both chorioam-
nionitis and postpartum endometritis or endomyometritis (PPE),
two of the most common infections surrounding childbirth [4].
These complications are likely to be inconsistently reported. ICD-
10 codes for ‘‘sepsis following incomplete or complete abortion”
(O03.87) and ‘‘endometritis following delivery” (O86.12) do not
include any diagnostic criteria (see Figs. 1–3).
Early identification and appropriate management of these infec-
tions is essential for prevention of maternal and infant morbidity
and mortality. Efforts have been made to standardize the defini-
tions for maternal infectious conditions or sepsis in order to
improve identification of the condition, facilitating timely treat-
ment based upon prompt identification, and assessment of the bur-
den of maternal puerperal sepsis across settings [5,6].
Fig. 1. Postpartum endometritis diagnostic levels of certainty.
Fig. 2. Infection following incomplete or complete abortion, diagnostic levels of certainty 1 and 2.
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are important pregnancy outcomes and should be reported in vac-
cine trials, the variability in terms used and lack of standardized
diagnostic criteria make interpretation of available data challeng-
ing. Our aim is to provide guidance for the appropriate diagnosis
of postpartum endometritis (PPE) in studies of maternal vaccina-
tion and to improve data quality by harmonizing the definitions,
allowing comparability across studies. In addition to PPE, we have
also included levels of evidence for diagnostic criteria for septic
abortion, since the clinical signs and symptoms and the microbial
pathogens are similar to those of PPE [7]. The distinction between
the PPE and septic abortion is frequently based solely upon the ges-tational age at the time the pregnancy concludes. Chorioamnioni-
tis, or intra-amniotic infection, is discussed in a related article [8].1.1.1. Postpartum endometritis (PPE)
1.1.1.1. Incidence, microbiology and risk factors for postpartum
endometritis. Infection following childbirth occurs commonly.
Although the incidence of puerperal sepsis, including both PPE
and chorioamnionitis, varies widely worldwide, estimates range
from less than 1–10% [9,10]. As with maternal mortality in general,
death and morbidity from puerperal sepsis are more common in
low-resource settings compared to high-resource settings [2].
Fig. 3. Infection following incomplete or complete abortion, diagnostic level of certainty 3.
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quent cause of death in the 3–7 days following delivery [11].
Postpartum endometritis is one of the primary causes of mater-
nal infection following delivery, occurring after 1–3% of vaginal
births and in up to 27% of cesarean deliveries [12]. Other common
causes of postpartum febrile morbidity include mastitis, urinary
tract infection, and abdominal or perineal wound infection. The
relative frequency of these infections seems to vary by clinical set-
ting. Mastitis (3–4.5%), followed by urinary tract infection (2.4–3%)
and endometritis (1.7–2%) were the most common postpartum
infections identified in an observational study in Sweden [13]. A
prospective study in Uganda found that endometritis was the most
common in-hospital postpartum infection (1.8%) [14].
Postpartum endometritis is an infection of the decidua, or
uterine lining. Because the myometrial, or muscular layer, is also
often involved in postpartum uterine infection, the term ‘‘endomy-
ometritis” is often used to describe the infection. It is typically
polymicrobial, involving both facultative and anaerobic bacteria;
genital mycoplasmas and sexually transmitted organisms such at
C. trachomatis have also been found in endometrial biopsy
specimens of patients with endometritis [15]. The microbiology
of PPE found in low- and middle-income countries (LMIC) differs
from that found in high-income countries, with organisms such
as E. coli, Proteus spp, N. gonorrhoea, and S. pneumonia isolated most
frequently in LMIC [16]. Group B Streptococcus, frequently found in
the genital tracts of pregnant women, is thought to be responsible
for a significant number of infections in postpartum women
worldwide [17]. Group A Streptococcus infection, while relatively
rare, is associated with a particularly rapid and severe course of
postpartum endometritis and with rapidly progressive soft
tissue infections [18]. Overall mortality approaches 20% in cases
of Group A Streptococcus, and increases to 60% if septic shock is
present [19–21].
The most important risk factor for postpartum endometritis is
cesarean delivery. This risk is 21 times higher when the cesarean
occurs following labor [22]. Other risk factors include maternalBMI > 35 kg/m2, prolonged rupture of membranes, chorioamnioni-
tis, lack of antibiotic prophylaxis, poor nutrition, location of deliv-
ery, low socioeconomic status and multiple vaginal examinations
[10,12,18,23,24].
1.1.1.2. Diagnosis of postpartum endometritis. Postpartum
endometritis is a clinical diagnosis, usually defined as maternal
pyrexia together with physical signs of endometrial infection. Clin-
ical signs and symptoms usually include fever and one or more of
the following:uterine tenderness, abnormal vaginal discharge or
odor, and delay in the rate of reduction of size of the uterus [25].
Other laboratory evidence is often used to support the diagnosis
of infection, such as an elevated white blood cell count; an elevated
blood lactic acid concentration is useful in identifying hypoperfu-
sion related to sepsis. While detection of bacteremia with blood
cultures can be useful to tailor antibiotic treatment in complicated
infections (for example, in immunocompromised patients), the
polymicrobial nature of most infections limits its utility; thus, in
most patients with uncomplicated infection, broad-spectrum
antibiotic treatment is recommended and usually effective
[26,27]. Abnormal vital signs consistent with sepsis physiology
(such as elevated or depressed temperature, hypotension, tachy-
cardia, tachypnea or bradypnea, hypoxia, leukocytosis or leukope-
nia, bandemia (excess immature white blood cells), and lactic
acidosis) can help identify women requiring urgent evaluation
and treatment [28,29]. Endometrial bacterial cultures are challeng-
ing to obtain without contamination [30] and rarely impact treat-
ment decisions; thus they are not routinely performed in most
settings [31]. One exception may be Group A Streptococcus, which
remains extremely sensitive to penicillin.
1.1.2. Infection following incomplete or complete abortion
1.1.2.1. Incidence, microbiology and risk factors for infection following
incomplete or complete abortion. Abortion is a common pregnancy
outcome. Spontaneous abortion, or pregnancy loss prior to
22 weeks gestation, has been described in a related document
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weeks 5 and 20 of pregnancy ranged from 11% to 22% in one sys-
tematic review [33]. The rate of infection following spontaneous
abortion is low.
Induced abortion is the termination of pregnancy through med-
ical or surgical procedures. Approximately 25% of pregnancies end
in induced abortion worldwide, and the annual rate of abortion for
reproductive age women is approximately 35 per 1000[34]. In
high-income countries (HIC) with legal abortion, the rate of fatal
sepsis following medically induced abortion is very low (<1/
10,000) [35], with recent studies reporting an overall incidence
of infection in this population of 0.1–0.5% [36,37]. In women in
HIC undergoing surgical abortion procedures (i.e., dilation and
curettage), the rate of infection is reported to be 0.0–0.4%
[37,38]. Worldwide, the rate of infection after surgical abortion is
0.1–4.7% [39]. Rates of infection related to abortion in LMIC is dif-
ficult to ascertain, but given that almost all unsafe abortions occur
in developing countries [40], this statistic is likely to be higher than
in HIC.
Infection following incomplete or complete abortion (induced
or spontaneous), results from infection of the products of
conception retained within the uterine cavity. While most bacte-
ria that cause infection following abortion are genital flora (e.g.
Group B streptococcus, B. fragilis, E. coli), anaerobic bacteria are
particularly associated with the condition and found in 60% of
women with positive blood cultures; bacteria causing genital
infection have also been implicated in infection following abortion
(N. gonorrhoea, C. trachomatis, Trichomonas) [41–43]. C. perfringens
and Group A streptococcus are rare isolates in these cases, but are
particularly virulent secondary to their ability to produce toxins
[41,44,45].
Uterine instrumentation increases the risk of infection follow-
ing abortion [7]. Retained products of conception provide a nidus
for the development of infection. Many studies report an increased
incidence of post-abortion complications in settings where abor-
tion laws are restrictive [46–48]. Treatment delays are thought to
contribute significantly to mortality associated with induced abor-
tion [7]. Unsafe/unsterile conditions in which any abortion
(regardless of presence of fetal cardiac activity) is performed also
increase the risk of infection.1.1.2.2. Diagnosis of infection following incomplete or complete
abortion. As with postpartum endometritis, infection following
incomplete or complete abortion is a clinical diagnosis in a patient
with an incomplete abortion or following a completed abortion in
which there is pyrexia and evidence of uterine tenderness. Peri-
tonitis may be present. Retained products of conception, purulent
discharge and vaginal bleeding are common signs associated with
the condition. While not required for the diagnosis or prior to
treatment, culture data is often obtained; products of conception
should be sent for culture and Gram stain, if available [49].1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for postpartum endo-
metritis and infection following incomplete or complete abortion as
adverse events following immunization during pregnancy
Following the process described in the overview paper [50] as
well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Postpartum Endometritis and Sepsis/Infec-
tion after Abortion Working Group was formed in 2018 and
included members of clinical, academic, public health, research
and industry background. The composition of the working and ref-
erence group as well as results of the web-based survey completedby the reference group with subsequent discussions in the working
group can be viewed at: http://www.brightoncollaboration.org/in-
ternet/en/index/working_groups.html.
To guide the decision-making for the case definition and guide-
lines, a literature search was performed using Medline, Embase
and the Cochrane Libraries, including the terms ‘‘endometritis,”
‘‘postpartum,” ‘‘postpartum sepsis,” ‘‘septic abortion,” ‘‘abortion,”
‘‘postpartum inflammation,” and ‘‘postpartum fever.” Exhaustive
search strategies were implemented using appropriate keywords,
accepted MeSH words, and combinations thereof. All abstracts
were screened for possible reports of abortion following immu-
nization. Searches were restricted to references in English, and
involving only human subjects. Multiple general medical, pedi-
atric, obstetrics and infectious disease textbooks were also
searched.
The search and screening resulted in the identification of arti-
cles with potentially relevant material for further evaluation. This
literature provided several different general definitions for PPE
and infection following abortion, their epidemiology, numerous
descriptions for causes and/or risk factors and the diagnostic crite-
ria put forth. Most publications addressing postpartum endometri-
tis and infection following abortion following immunization were
case reports of single cases or case series describing various preg-
nancy outcomes, for which terminology was very inconsistent and
very few used case definitions.
1.3. Rationale for selected decisions about the case definition of post-
partum endometritis and infection following incomplete or complete
abortion as adverse events following immunization during pregnancy
1.3.1. Related term(s)
Postpartum endomyometritis is a term that is increasingly uti-
lized to describe uterine infection after childbirth in order to high-
light that the infection does not solely involve the endometrial
layer of the uterus, but also the myometrial, or muscular layer.
There are several terms in use to describe sepsis or infection
after abortion, including ‘‘septic abortion,” ‘‘post-abortion infec-
tion,” and ‘‘infection after miscarriage or abortion.” For the pur-
poses of this document, we will use the terms ‘‘postpartum
endometritis,” and ‘‘infection following incomplete or complete
abortion.”
1.3.2. Formulating a case definition that reflects diagnostic certainty:
Weighing specificity versus sensitivity
It needs to be re-emphasized that the grading of definition
levels is entirely concerned with diagnostic certainty, not clinical
severity of an event. Thus, a clinically very severe event may appro-
priately be classified as Level Two or Three rather than Level One if
it could reasonably be non-abortion related. Detailed information
about the severity of the event should always be recorded, as spec-
ified by the data collection guidelines.
The number of symptoms and/or signs that will be documented
for each case may vary considerably. Our case definition has been
formulated such that the Level One definition is highly specific for
the condition. As maximum specificity normally implies a loss of
sensitivity, two additional diagnostic levels have been included
in the definition, offering a stepwise increase of sensitivity from
Level One down to Level Three, while retaining an acceptable level
of specificity at each level. In this way it is hoped that all possible
cases of post-partum endometritis and infection following incom-
plete or complete abortion can be captured.
1.3.3. Rationale for individual criteria or decision made related to the
case definition
There is a need to consider data sources and availability of
existing data when defining pregnancy outcomes in research. The
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used terms differ in the literature. Flexibility and alignment with
existing definitions where studies/surveillance are performed are
necessary to ensure comparability and interpretation of data.
Sometimes these data are not made available.1.3.4. Determination of the gestational age at onset of the event
Proposed algorithms for defining abortion, fever and for
estimating gestational age for studies in various settings are
presented in related manuscripts [32,51,52]. We propose utilizing
these algorithms when reporting cases of postpartum endometritis
or infection/sepsis following abortion following vaccine
administration.1.3.5. Determination of fever
Maternal fever is defined as the endogenous elevation of at least
one measured body temperature of 38 C, as measured by any
validated device [52].1.3.6. Gestational age cut-offs for definition of sepsis/infection after
abortion
The gestational age used to define second trimester abortion
varies widely among resource settings. However, we have chosen
to utilize the GAIA project definition of abortion using the Brighton
guidelines in order to ensure harmonization across GAIA defini-
tions, resulting in the fewest number of missed cases of post-par-
tum endometritis and infection after complete or incomplete
abortion as possible. The GAIA definition of a spontaneous abortion
is a pregnancy loss that occurs up to 21 weeks 6 days, with out-
comes after that gestational age pertaining to the stillbirth or pre-
term birth categories. We emphasize that this gestational age cut-
off should be used for research and data collection purposes only,
and is not intended to inform or impact clinical care. Intrauterine
infection diagnosed after 21 weeks 6 days will pertain to the GAIA
definition of Chorioamnionitis [8].1.3.7. Timing post immunization in pregnancy
The time interval from immunization to onset of postpartum
endometritis or sepsis/infection after abortion is not part of the
definition, but it is recommended to be used in the data analysis
to examine factors such as temporal clusters as well as determin-
ing whether the outcome of interest occurred before or after the
vaccine exposure. Where feasible, details of this interval should
be assessed and reported as described in the data collection guide-
lines (see guideline 34, Section 3.2).1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper [50], the case definition is
accompanied by guidelines that are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis
and presentation. Neither case definition nor guidelines are
intended to guide or establish criteria for management of ill
infants, children, or adults, but were instead developed to improve
data comparability.1.5. Periodic review
Similar to all Brighton Collaboration case definitions and
guidelines, review of the definition with its guidelines is planned
on a regular basis (i.e. every three to five years) or more often if
needed.2. Case definition of postpartum endometritis and infection
after incomplete or complete abortion and ascertainment of
levels of certainty
2.1. Postpartum endometritis
2.1.1. Level 1 (Highest level, gold standard diagnosis, highest
specificity)
Live birth or stillbirth within 42 days
AND
Measured fever to 38 degrees Celsius
AND
Evidence of uterine infection based on clinical findings that
may include uterine tenderness, pelvic pain, abnormal
vaginal discharge or odor, and delay in the rate of reduction
of size of the pospartum uterus
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture2.1.2. Level 2 (Missing at least one confirmatory diagnostic parameter;
moderate sensitivity and specificity)
2A
Live birth or stillbirth within 42 days
AND
Patient report of fever
AND
Evidence of uterine infection based on clinical exam
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture
2B
Live birth or stillbirth within 42 days
AND
Measured fever to 38 degrees Celsius
AND
Patient report of evidence of symptoms consistent with
uterine infection (e.g., pelvic pain, uterine tenderness,
abnormal vaginal discharge or odor)
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture2.1.3. Level 3 (Less specificity)
3A
Live birth or stillbirth within 42 days
AND
Patient report of fever
AND
Evidence of uterine infection based on clinical exam
3B
Live birth or stillbirth within 42 days
AND
Measured fever to 38 degrees Celsius
(continued on next page)
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Patient reports symptoms consistent with uterine infection,
as outlined above
3C
Live birth or stillbirth within 42 days
AND
Patient report of fever
AND
Patient report symptoms consistent with uterine infection, as
outlined above2.2. Infection following incomplete or complete abortion
2.2.1. Level 1 (Highest level, gold standard diagnosis, maximum
sensitivity and specificity)
Completed abortion or evidence of nonviable intrauterine
pregnancy with gestational age within predefined range for
selected abortion definition as assessed by maternal and/or
fetal parameters (Level 1) (using the GAIA-Brighton
Spontaneous Abortion and Ectopic Pregnancy Guidelines)
within 42 days
AND
Measured fever to 38 degrees Celsius
AND
Evidence of uterine infection based on clinical examination
(e.g., uterine tenderness, purulent vaginal discharge,
prolonged vaginal bleeding, or presence of retained
products of conception)
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture2.2.2. Level 2 (Missing at least one confirmatory diagnostic parameter,
remains sensitive and specific)
2A
Completed abortion or evidence of nonviable intrauterine
pregnancy with gestational age within predefined range for
selected abortion definition as assessed by maternal and/or
fetal parameters (Level 2) (using the Brighton Spontaneous
Abortion and Ectopic Pregnancy Guidelines) within 42 days
AND
Measured fever to 38 degrees Celsius
AND
Evidence of uterine infection based on clinical exam
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture
2B
Completed abortion or evidence of nonviable intrauterine
pregnancy with gestational age within predefined range for
selected abortion definition as assessed by maternal and/or
fetal parameters (Level 1–2) (using the Brighton
Spontaneous Abortion and Ectopic Pregnancy Guidelines)
within 42 days
AND
Patient report of fever
AND
Evidence of uterine infection based on clinical exam
ORMeasured fever to 38 degrees Celsius
AND
Patient report of evidence of uterine infection
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture2.2.3. Level 3. (Less sensitive, with specificity)
3A
Completed abortion or evidence of nonviable intrauterine
pregnancy with gestational age within predefined range for
selected abortion definition as assessed by maternal and/or
fetal parameters (Level 3) (using the Brighton Spontaneous
Abortion and Ectopic Pregnancy Guidelines) within 42 days
AND
Measured fever to 38 degrees Celsius
AND
Evidence of uterine infection based on clinical exam
OR
Patient report of fever
AND
Evidence of uterine infection based on clinical exam
OR
Measured fever to 38 degrees Celsius
AND
Patient report of evidence of uterine infection
AND
Exclusion of urinary tract infection by negative urine culture
or negative urine culture
3B
Completed abortion or evidence of nonviable intrauterine
pregnancy with gestational age within predefined range for
selected abortion definition as assessed by maternal and/or
fetal parameters (any level) (using the Brighton
Spontaneous Abortion and Ectopic Pregnancy Guidelines)
within 42 days
AND
Patient report of fever
AND
Evidence of uterine infection based on clinical exam
OR
Measured fever to 38 degrees Celsius
AND
Patient report of evidence of uterine infection
OR
Patient report of fever
AND
Patient report of evidence of uterine infection3. Guidelines for data collection, analysis and presentation of
postpartum endometritis and infection following incomplete
or complete abortion
It was the consensus of the Brighton Collaboration Postpar-
tum Endometritis and Infection or Sepsis following Complete or
Incomplete Abortion Working Group to recommend the following
guidelines to enable meaningful and standardized collection,
analysis, and presentation of information. However, implementa-
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availability of information may vary depending upon resources,
geographical region, and whether the source of information is
a prospective clinical trial, a post-marketing surveillance or
epidemiological study, or an individual report of postpartum
endometritis or infection following incomplete or complete
abortion. Also, as explained in more detail in the overview
paper in this volume, these guidelines have been developed by
this working group for guidance only, and are not to be consid-
ered a mandatory requirement for data collection, analysis, or
presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of available pregnancy outcome data following immunization
to allow comparability. The guidelines are not intended to guide
the primary reporting of abortion to a surveillance system. Investi-
gators developing a data collection tool based on these data collec-
tion guidelines also need to refer to the criteria in the case
definition, which are not repeated in these guidelines.
Guidelines 1–46 below have been developed to address data
elements for the collection of adverse event information as
specified in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use [ICHTR doc],
and the form for reporting of drug adverse events by the Council
for International Organizations of Medical Sciences [CIOMS].
These data elements include an identifiable reporter and
patient, one or more prior immunizations, and a detailed
description of the adverse event, in this case, of abortion follow-
ing immunization. The additional guidelines have been devel-
oped as guidance for the collection of additional information to
allow for a more comprehensive understanding of abortion fol-
lowing immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person2 reporting postpar-
tum endometritis or infection following incomplete or com-
plete abortion as specified by country specific data
protection law.
(3) Relationship of the reporter to the vaccine recipient [e.g.,
immunizer (clinician, nurse) attending physician, family
member [indicate relationship], self [vaccine recipient],
other.
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants
(i.e. pregnant women), as appropriate, the following information
should be recorded:
(4) Case study participant identifiers (first name initial followed
by last name initial) or code (or in accordance with country-
specific data protection laws).
(5) Date of birth, age of patient
(6) Gestational age at event or number of days postpartum2 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.(7) Country of residence
(8) Occupation(s)
3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(9) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
(10) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term
effect (e.g. immunoglobulins, blood transfusion and
immune-suppressants) or substance abuse (e.g. narcotics
or other recreational drug, alcohol or smoking).
(11) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI), in particular
occurrence of abortion after a previous immunization.
(12) Clinical confirmation of pregnancy prior to maternal
immunization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(13) Date and time of immunization(s).
(14) Description of all vaccine (s) onset of PPE or infection follow-
ing abortion (name of vaccines, manufacturer, lot number,
expiration date, multi or mono dose vial, volume (e.g. 0.25
Ml, 0.5 mL, etc.), dose number if part of series of immuniza-
tions against the same disease(s), and the manufacturer, lot
number, and expiration date of any diluents used).
(15) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(16) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(17) Needle length and gauge.
(18) If the immunization is part of:– Routine immunization program
– Preventive mass immunization campaign
– Mass immunization campaign for outbreak response
– Domestic travel from nonendemic to endemic area
– International travel
– Occupational risk3.1.4. The adverse event
For all cases at any level of diagnostic certainty and for reported
events with insufficient evidence, the criteria fulfilled to meet the
case definition should be recorded.
Specifically document (if available):
(19) Clinical description of signs and symptoms of postpartum
endometritis or infection following incomplete or complete
abortion, and if there was medical confirmation of the event
(i.e. patient seen by physician).
7592 C.E. Rouse et al. / Vaccine 37 (2019) 7585–7595(20) Date/time of onset3, first observation4 and diagnosis5; as well
as end of episode6 and final outcome7, if appropriate (e.g. if
the event no longer meets the case definition of abortion at
the lowest level of the definition).
(21) Concurrent signs, symptoms, exposures and diseases.

















fetus).– Pregnancy details: date of last normal menstrual period,
ultrasound examinations, antenatal care visits, preg-
nancy-related illnesses and complications.
– Results of ultrasound examinations, antenatal care visits,
laboratory examinations, other clinical tests, surgical
and/ or pathological findings and diagnosis preferable
to perform at reliable and accredited laboratories. If more
than one measurement of a particular parameters is
taken and recorded, the value corresponding to the lar-
gest deviation from the expected normal value or range
of parameter should be reported.
– Event details: specifically document (if available) mode
of treatment (e.g. IV antibiotics, etc) and complications,
if any (e.g. hemorrhage, sepsis, etc.).(23) Measurement/testing
– Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
– Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
– Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.(24) Treatment given for postpartum endometritis or infection
following incomplete or complete abortion, especially spec-
ify what and dosing, if applicable.
(25) Outcome6 at last observation. Add descriptions if maternal
death occurred. Also, for multiple gestation, if concomitant
twin death occurred. For example:
– Recovery to pre- immunization health status
– Spontaneous resolution
– Ongoing treatment
– Persistence of the event
– Significant complications of treatment
– Death and description of any other outcome(26) Objective clinical evidence supporting classification of the
event as ‘‘serious”8 (i.e. results in death), for example, a
pathology report.
(27) Exposures other than the immunization before and after
immunization (e.g. trauma, induced, environmental) consid-
ered potentially relevant to the reported event.date and/or time of onset is defined as the time post immunization, when the
n or symptom indicative for abortion occurred. This may only be possible to
ine in retrospect.
date and/or time of first observation of the first sign or symptom indicative
tion can be used if date/time of onset is not known.
date of diagnosis of an episode is the day post immunization when the event
case definition at any level.
end of an episode is defined as the time the event no longer meets the case
n at the lowest level of the definition.
mple: recovery to pre-immunization health status, spontaneous resolution,
utic intervention, persistence of the event, sequelae, death.
AEFI is defined as serious by international standards if it meets one or
f the following criteria: 1) it results in death, 2) is life-threatening, 3) it
s inpatient hospitalisation or results in prolongation of existing hospitali-
4) results in persistent or significant disability/incapacity, 5) is a congenital
y/birth defect, 6) is a medically important event or reaction. For abortion,
nt meets the definition of serious (i.e. it results in death of the embryo/3.1.5. Miscellaneous/ general
(28) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event (i.e. the outcome of the preg-
nancy or postpartum period is captured).
(29) Methods of data collection should be consistent within and
between study groups, if applicable.
(30) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1 to 27.
(31) Investigators of patients with postpartum endometritis or
infection following incomplete or complete abortion should
provide guidance to reporters to optimize the quality and
completeness of information provided.
(32) Reports of these events should be collected throughout the
study period regardless of the time elapsed between immu-
nization and the adverse event. If this is not feasible due to
the study design, the study periods during which safety data
are being collected should be clearly defined.
(33) The duration of surveillance period for these events should
be predefined where applicable (e.g., clinical studies or









the eve– Biologic characteristics of the vaccines (e.g., live attenu-
ated versus inactivated component vaccines).
– Biologic characteristics of the vaccine- targeted disease.
– Biologic characteristics of abortion, including patterns
identified in previous trials (e.g. early- phase trials) and
– Biologic characteristics of the target population (e.g.,
nutrition, underlying disease like immunesuppressive ill-
ness).(34) Methods of data collection should be consistent within and
between study groups or surveillance systems, if applicable.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on postpartum endometritis and infection follow-
ing incomplete or complete abortion to allow for comparability of
data, and are recommended as an addition to data analyzed for the
specific study question and setting.
(36) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
3.2.1. Event classification in 5 categories9
3.2.1.1. Event meets case definition.
(1) Level 1: Criteria as specified in the Postpartum Endometritis or
Infection Following Incomplete Or Complete Abortion case
definitionetermine the appropriate category, the user should first establish, whether a
d event meets the criteria for the lowest applicable level of diagnostic
y, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
n is met, and there is evidence that the criteria of the next higher level of
tic certainty are met, the event should be classified in the next category. This
h should be continued until the highest level of diagnostic certainty for a
vent could be determined. Major criteria can be used to satisfy the
ment of minor criteria. If the lowest level of the case definition is not met, it
be ruled out that any of the higher levels of diagnostic certainty are met and
nt should be classified in additional categories four or five.
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Infection Following Incomplete Or Complete Abortion case
definition
(3) Level 3: Criteria as specified in the Postpartum Endometritis or
Infection Following Incomplete Or Complete Abortion case
definition3.2.1.2. Event does not meet case definition.
3.2.1.2.1. Additional categories for analysis.
(4) Reported abortion with insufficient evidence to meet the
case definition10
(5) Not a case of postpartum endometritis or infection following
incomplete or complete abortion11
(37) The interval between immunization and reported event
could be defined as the date/time of immunization (last vac-
cination) to the date/time of onset2 of the event, consistent
with the definition. If few cases are reported, the concrete
time course could be analyzed for each; for a large number
of cases, data can be analyzed in the following increments
for identification of temporal clusters:
3.2.2. Subjects with postpartum endometritis or infection following
incomplete or complete abortion by interval to presentationInterval* Number
 24 hrs. after immunization
2 -  7 days after immunization
8 -  42 days after immunization
> 42 days after immunization
Weekly unit increments thereafter3.2.3. Total
(38) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(39) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.
(40) Data on postpartum endometritis or infection following
incomplete or complete abortion obtained from subjects
receiving a vaccine should be compared with those obtained
from an appropriately selected and documented control
group(s) to assess background rates in non-exposed popula-
tions, and should be analyzed by study arm and dose where
possible, e.g. in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on postpartum endometritis or10 If the evidence available for an event is insufficient because information is
missing, such an event should be categorised as ‘‘reported abortion with insufficient
evidence to meet the case definition”.
11 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of abortion”.infection following incomplete or complete abortion following
immunization to allow for comparability of data, and are recom-
mended as an addition to data presented for the specific study
question and setting. Additionally, it is recommended to refer to
existing general guidelines for the presentation and publication
of randomized controlled trials, systematic reviews, and meta-
analyses of observational studies in epidemiology (e.g. statements
of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM), and of Meta-analysis Of Observational
Studies in Epidemiology (MOOSE), respectively) [Consort 2001,
Moher 1999, Stroup 2000].
(41) All reported events of postpartum endometritis or infection
following incomplete or complete abortion should be pre-
sented according to the categories listed in guideline 33.
(42) Data on possible events should be presented in accordance
with data collection guidelines 1–32 and data analysis
guidelines 33–37.
(43) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(44) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(45) If the distribution of data is skewed, median and inter-quar-
tile range are usually the more appropriate statistical
descriptors than a mean. However, the mean and standard
deviation should also be provided.
(46) Any publication of data on abortion should include a
detailed description of the methods used for data collection
and analysis as possible. It is essential to specify:12 Use
respecti
ration.o The study design;
 The method, frequency and duration of monitoring for
abortion;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset2 and/or the date of first obser-
vation3 and/or the date of diagnosis4 was used for analy-
sis; and
 Use of this case definition for abortion, in the abstract or
methods section of a publication12.of this document should preferably be referenced by referring to the
ve link on the Brighton Collaboration website (http://www.brightoncollabo-
rg).
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